Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Sesen Bio, Inc.
EIR
•Sesen Bio, Inc.•June 3, 2021

Sesen Bio, Inc. – FDA EIR, Jun 3, 2021

Record Details

Sesen Bio, Inc. was subject to a high-priority FDA Bioresearch Monitoring (BIMO) inspection from May 24 to June 3, 2021, focusing on its responsibilities as the sponsor for an Investigational New Drug (IND) study. Although this particular inspection did not result in an FDA Form 483, management was presented with several significant issues, some of which echoed problems previously identified at two clinical investigator sites and a contract research organization (CRO) involved in the same study that had received 483s.Key issues raised during the inspection included challenges in providing complete and timely documentation, the absence of Sesen's clinical operations Standard Operating Procedures (SOPs) until 2019, and a lack of vendor oversight SOPs. The FDA also noted gaps in meeting minutes between Sesen and its CRO, limited clinical operations staffing, and turnover of medical officers. Furthermore, data listings lacked essential dates, and certain source records were missing from the pharmacovigilance system.The inspection highlighted poor quality monitoring by the CRO, which prompted Sesen to implement a Remediation Plan and a Re-Monitoring Plan. These plans addressed concerns about missing safety data and disorganized site records, which collectively presented a significant risk to data quality and patient safety. It was also noted that a data management plan for long-term follow-up was not in place prior to data collection commencing.Sesen's President and CEO acknowledged these discussion items, committing to review and address them, including improving documentation, ensuring procedural plans are established proactively, and reinforcing overall oversight.

Company
Sesen Bio, Inc.
Inspection date
June 3, 2021
Product type
Biologics
Office
New England District Office
People
  • Alicia Dalley (issuing_officer)
  • Matthew C. Watson
View Company Profile

ID · ec36dfa5-8d70-4166-9c52-a346f592ceb3

Violation Codes1
21 CFR 211

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Sesen Bio, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.